JAGX: Jaguar Health Inc. Stocks News on January 19, 2025

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

JAGX

ACCESSWIRE

9 days ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

JAGX

ACCESSWIRE

11 days ago

Jaguar Health Presenting January 13 at Lytham 2025 Investor Healthcare Summit & January 14 at Biotech Showcase

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum

JAGX

ACCESSWIRE

12 days ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present January 12 at the Annual Neuroscience Innovation Forum

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications

JAGX

ACCESSWIRE

a month ago

Jaguar Health Announces Import of Coca Leaf From Peru by Joint Venture Magdalena Biosciences for Research in Treating Mental Health Indications

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

JAGX

ACCESSWIRE

a month ago

Phase 2 Study Initiated to Evaluate Jaguar Health's Crofelemer for Microvillus Inclusion Disease (MVID), an Ultrarare Congenital Diarrheal Disorder

FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera

JAGX

ACCESSWIRE

a month ago

FDA Approves Orphan-Drug Designation for Jaguar Health’s Crofelemer for Treatment of Diarrhea in Cholera

FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES

JAGX

CNW Group

a month ago

FILAMENT HEALTH ANNOUNCES IMPORT OF COCA LEAF FROM PERU BY JOINT VENTURE MAGDALENA BIOSCIENCES

Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer

JAGX

ACCESSWIRE

a month ago

Ladenburg Thalmann to Host Scientific Showcase December 18, 2024 About Rare Disease Clinical Development Efforts for Jaguar Health's Crofelemer

Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)

JAGX

ACCESSWIRE

a month ago

Significant Positive Results with Jaguar Health's Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients Presented at San Antonio Breast Cancer Symposium (SABCS)

Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)

JAGX

ACCESSWIRE

a month ago

Poster Presentation Describing the Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea (CTD) in Breast Cancer Patients to Take Place December 11, 2024 at San Antonio Breast Cancer Symposium (SABCS)

U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins

JAGX

ACCESSWIRE

a month ago

U.S. Investigator-Initiated Trial (IIT) to Evaluate Jaguar Health’s Crofelemer for Short Bowel Syndrome with Intestinal Failure (SBS-IF) Begins

Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine

JAGX

ACCESSWIRE

a month ago

Article about Canalevia-CA1, Jaguar Health's Prescription Drug Conditionally Approved by the FDA for the Treatment of Chemotherapy-Induced Diarrhea in Dogs, Published in PetVet Magazine

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

JAGX

GlobeNewswire

a month ago

Presenting on the Emerging Growth Conference 77 Day 2 on December 5th Register Now

Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

JAGX

ACCESSWIRE

2 months ago

Jaguar Health Participating in December 3-5 Pet Connect Conference with Goal of Identifying Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference

JAGX

ACCESSWIRE

2 months ago

Jaguar Health Presenting December 3rd at NobleCon20 and December 5th at the Emerging Growth Conference

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

JAGX

ACCESSWIRE

2 months ago

Jaguar Health Seeking Partner to Develop and Commercialize NP300 Second-Generation Antisecretory Prescription Drug Candidate for Treatment of General Diarrhea in Dogs

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

JAGX

ACCESSWIRE

2 months ago

Jaguar Health Family Company Napo Therapeutics Named “Best Pharmaceuticals Innovator of the Year - Europe”

Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

JAGX

Simply Wall St.

2 months ago

Jaguar Health Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

JAGX

GuruFocus.com

2 months ago

Jaguar Health Inc (JAGX) Q3 2024 Earnings Call Highlights: Revenue Growth and Strategic ...

Jaguar Health Reports Third Quarter 2024 Financial Results

JAGX

ACCESSWIRE

2 months ago

Jaguar Health Reports Third Quarter 2024 Financial Results

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates

JAGX

ACCESSWIRE

2 months ago

Jaguar Health to Hold Investor Webcast Wednesday, November 13th at 8:30 AM Eastern Regarding Q3 2024 Financials & Corporate Updates

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs

JAGX

ACCESSWIRE

2 months ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea in Dogs

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)

JAGX

ACCESSWIRE

2 months ago

Abstract Describing Significant Results of Crofelemer for Cancer Therapy-Related Diarrhea in Breast Cancer Patients Accepted for Presentation at San Antonio Breast Cancer Symposium (SABCS)

$Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting$

JAGX

ACCESSWIRE

3 months ago

Significant Positive Results with Jaguar Health's Crofelemer for Chronic Refractory Diarrhea in IBS-D, Presented at American College of Gastroenterology Annual Meeting

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.

JAGX

ACCESSWIRE

3 months ago

Jaguar Health Launches FDA-Approved Oral Mucositis Prescription Product Gelclair in the U.S.

JAGX

ACCESSWIRE

3 months ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

JAGX

ACCESSWIRE

3 months ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, to Present October 16 at BIO Investor Forum

JAGX

GuruFocus.com

3 months ago

Jaguar Health Inc (JAGX) Q2 2024 Earnings Call Highlights: Revenue Growth Amidst Financial ...

Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial

JAGX

ACCESSWIRE

3 months ago

Jaguar Health Submits Abstract for First-of-Kind Study Evaluating the Impact of Diarrhea from Cancer Therapies in Breast Cancer Patients Who Received Placebo in its OnTarget Phase 3 Trial

Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup

JAGX

Clinical Trials Arena

4 months ago

Jaguar’s diarrhoea drug shows benefit in Phase III breast cancer subgroup

Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer

JAGX

ACCESSWIRE

4 months ago

Jaguar Health Reports Statistically Significant Improvement in Breast Cancer Patients in its Phase 3 OnTarget Trial for its Cancer Supportive Care Drug Crofelemer

Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Survivors

JAGX

ACCESSWIRE

4 months ago

Jaguar Health Scientific Advisory Board Member to Share Poster Presentation at American Society of Clinical Oncology (ASCO) Quality Care Symposium About the Methodologies Involved in Designing an Advocate-Led Quality of Life Survey for Cancer Patients and Survivors

Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

JAGX

ACCESSWIRE

4 months ago

Jaguar Health to Participate in the Lytham Partners Fall 2024 Investor Conference on October 1, 2024

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch

JAGX

ACCESSWIRE

4 months ago

Jaguar Health to Spotlight Company's Commercial Focus on Cancer Supportive Care at American Society for Radiation Oncology (ASTRO) Annual Meeting for FDA-Approved Gelclair Oral Mucositis Product in Advance of October 2024 Gelclair Launch

Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference

JAGX

ACCESSWIRE

4 months ago

Jaguar Health to Present September 19 at the MedInvest Biotech & Pharma Investor Conference

Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

JAGX

ACCESSWIRE

4 months ago

Jaguar Health Appoints Industry Veteran to Head Sales for Company’s Commercialized Oncology and HIV Products Including October 2024 Launch of Gelclair for Cancer Supportive Care

Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference

JAGX

ACCESSWIRE

4 months ago

Jaguar Health to Present at the September 9-11 H.C. Wainwright Annual Global Investment Conference

Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

JAGX

ACCESSWIRE

4 months ago

Jaguar Health Celebrates National Service Dog Month: With its Supportive Cancer Care Drugs, Jaguar is Dedicated to the Health and Wellbeing of People and Dogs

New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones

JAGX

ACCESSWIRE

4 months ago

New Innovators with Jane King Interview with Jaguar Health CEO Lisa Conte Spotlights Company’s Near-Term Commercial & Development Milestones

JAGX

MT Newswires

5 months ago

Jaguar Health Awarded Patent in Jordan for Short Bowel Syndrome Treatment

Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

JAGX

ACCESSWIRE

5 months ago

Patent Issued in Jordan Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award

JAGX

ACCESSWIRE

5 months ago

Key Collaborator of Jaguar Health Joint Venture Magdalena Biosciences Receives Prestigious Alzheimer's Association Award

JAGX

MT Newswires

5 months ago

Jaguar Health Reports Issue of Hong Kong Patent for Short Bowel Syndrome Treatment Methods

JAGX

ACCESSWIRE

5 months ago

Issuance of New Hong Kong Patent Bolsters IP Protection for Jaguar Health in the Treatment of Short Bowel Syndrome (SBS)

Jaguar Health Second Quarter 2024 Earnings: Misses Expectations

JAGX

Simply Wall St.

5 months ago

Jaguar Health Second Quarter 2024 Earnings: Misses Expectations

Jaguar Health Reports Second Quarter 2024 Financial Results

JAGX

ACCESSWIRE

5 months ago

Jaguar Health Reports Second Quarter 2024 Financial Results

REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients

JAGX

ACCESSWIRE

5 months ago

REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, August 13th at 8:30 AM Eastern to Review Q2 Earnings and Further Review Phase 3 OnTarget Trial’s Clinically Meaningful Results in Breast and Lung Cancer Patients

JAGX

MT Newswires

5 months ago

Jaguar Health to Detail Regulatory Strategy for Antidiarrheal Drug for Cancer Patients Next Week

Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy

JAGX

ACCESSWIRE

6 months ago

Elaine Elisabetsky, PhD, Member of Jaguar Health's Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia at the University of Illinois Chicago College of Pharmacy

JAGX

ACCESSWIRE

6 months ago

Two Investigator-Initiated Responder Analysis Trials of Jaguar Health's Crofelemer Show Significant Positive Results for Chronic Refractory Diarrhea in IBS-D: Data Accepted for Presentation at American College of Gastroenterology 2024 Annual Meeting

JAGX

ACCESSWIRE

6 months ago

Issuance of New European Patent Bolsters IP Protection for Jaguar Health in the Treatment of Congenital Diarrheal Disorders (CDDs)

JAGX

MT Newswires

6 months ago

Top Midday Decliners

JAGX

MT Newswires

6 months ago

Sector Update: Health Care Stocks Advance in Afternoon Trading

JAGX

MT Newswires

6 months ago

Jaguar Health Shares Plunge After Cancer Therapy-Related Diarrhea Treatment Fails to Meet Primary Goal

Jaguar Health shares slump following Phase III Mytesi failure

JAGX

Clinical Trials Arena

6 months ago

Jaguar Health shares slump following Phase III Mytesi failure

JAGX

ACCESSWIRE

6 months ago

Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer

Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning

JAGX

ACCESSWIRE

6 months ago

Jaguar Health to Report Phase 3 OnTarget Trial Results for Its Cancer Supportive Care Drug Crofelemer on July 23rd and Hold Investor Webcast that Morning

JAGX

MT Newswires

6 months ago

Jaguar Health Unit Secures New European, Australian Patents; Shares Rise

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement

JAGX

ACCESSWIRE

7 months ago

Jaguar Health Regains Compliance with Nasdaq's Bid Price Requirement

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

JAGX

ACCESSWIRE

7 months ago

Jaguar Health Reports Approval of All Proposals at June 2024 Annual Meeting of Stockholders

Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024

JAGX

ACCESSWIRE

7 months ago

Jaguar Health to Report Pivotal Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer on or Before July 23, 2024

Catherine Wood's Strategic Acquisition of PagerDuty Inc Shares

JAGX

GuruFocus.com

7 months ago

Catherine Wood's Strategic Acquisition of PagerDuty Inc Shares

Insider Sale at Cogent Communications Holdings Inc (CCOI): CFO Thaddeus Weed Sells 2,400 Shares

JAGX

GuruFocus.com

7 months ago

Insider Sale at Cogent Communications Holdings Inc (CCOI): CFO Thaddeus Weed Sells 2,400 Shares

Gluckstein Lawyers Involved in Landmark Ruling Against Ukraine International Airlines in Flight PS 752 Case

JAGX

CNW Group

7 months ago

Gluckstein Lawyers Involved in Landmark Ruling Against Ukraine International Airlines in Flight PS 752 Case

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

JAGX

Yahoo Finance Video

7 months ago

FDA panel votes to recommend Eli Lilly's Alzheimer's drug

JAGX

GlobeNewswire

7 months ago

Chu Vision Institute Unveils Comprehensive Guide to LASIK Recovery and Aftercare, Pioneering Patient Care in Minneapolis

California seeks company profits in Big Oil climate lawsuit

JAGX

Reuters

7 months ago

California seeks company profits in Big Oil climate lawsuit

JAGX

USA TODAY

7 months ago

S&P 500, Nasdaq post record closing highs; Fed meeting, CPI ahead

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

JAGX

Business Wire

7 months ago

Dutch Bros Inc. Announces Launch of Secondary Public Offering of Class A Common Stock

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024

JAGX

CNW Group

7 months ago

Media Advisory - Prime Minister's itinerary for Sunday, June 9, 2024

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

JAGX

ACCESSWIRE

7 months ago

Industry Report: The Cannabis Company that Soared Nearly 100% This Year: What's Behind InterCure's Surge

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

JAGX

Business Insider

7 months ago

Russia is doubling down on its de-dollarization efforts as Putin calls to reduce use of 'toxic' currencies

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

JAGX

Motley Fool

7 months ago

Nvidia May Be an Exciting Stock, but Its 10-for-1 Stock Split -- Like Most Stock Splits -- Is a Nothing Burger

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

JAGX

GlobeNewswire

7 months ago

4DMT Presents Injection-Free Subgroup Analyses from 4D-150 Phase 2 PRISM Randomized Dose Expansion Cohort in Wet AMD Patients with Severe Disease Activity & High Treatment Burden at the Clinical Trials at the Summit 2024 Meeting

Unifor members vote to strike at Manitoba Hydro

JAGX

CNW Group

7 months ago

Unifor members vote to strike at Manitoba Hydro

Croatia beat Portugal in Euro 2024 warm-up friendly

JAGX

AFP

7 months ago

Croatia beat Portugal in Euro 2024 warm-up friendly

Mark Cuban explains how he helped turn 300 of his employees into millionaires

JAGX

Business Insider

7 months ago

Mark Cuban explains how he helped turn 300 of his employees into millionaires

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

JAGX

ACCESSWIRE

7 months ago

Jaguar Health Announces New Employee Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

JAGX

MT Newswires

8 months ago

Top Premarket Gainers

JAGX

MT Newswires

8 months ago

Jaguar Health Expands Out-licensing Agreement With Magdalena Biosciences

Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia

JAGX

ACCESSWIRE

8 months ago

Jaguar Health Executes Out-License Deal with Joint Venture Magdalena Biosciences for Botanical Drug Candidate for Schizophrenia

Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea

JAGX

ACCESSWIRE

8 months ago

Investigator-Initiated Trial of Jaguar Health’s Crofelemer Yields Positive Results for Functional Diarrhea

Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product

JAGX

ACCESSWIRE

8 months ago

Jaguar Health to Initiate Commercial Footprint in Cancer Supportive Care at American Society of Clinical Oncology (ASCO) Annual Meeting with Exhibit Booth for FDA-Approved Gelclair Oral Mucositis Product

JAGX

MT Newswires

8 months ago

Jaguar Health Plans 1-for-60 Reverse Split Next Week

Jaguar Health, Inc. Announces Reverse Stock Split

JAGX

ACCESSWIRE

8 months ago

Jaguar Health, Inc. Announces Reverse Stock Split

JAGX

GuruFocus.com

8 months ago

Jaguar Health Inc (JAGX) Q1 2024 Earnings Call Transcript Highlights: Strategic Expansions and ...

Jaguar Health Reports First Quarter 2024 Financial Results

JAGX

ACCESSWIRE

8 months ago

Jaguar Health Reports First Quarter 2024 Financial Results

REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates

JAGX

ACCESSWIRE

8 months ago

REMINDER: Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates

Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe

JAGX

ACCESSWIRE

8 months ago

Jaguar Health Announces Submission of Clinical Trial Applications for Crofelemer for the Rare Disease Indications Microvillus Inclusion Disease (MVID) and Short Bowel Syndrome (SBS) in Europe

Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates

JAGX

ACCESSWIRE

8 months ago

Jaguar Health to Hold Investor Webcast Tuesday, May 14th at 8:30 AM Eastern Regarding Q1 2024 Financials & Corporate Updates

JAGX

MT Newswires

8 months ago

Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment

Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs

JAGX

ACCESSWIRE

8 months ago

Crofelemer, Jaguar Health’s Prescription Drug Conditionally Approved by the FDA for Chemotherapy-Induced Diarrhea in Dogs, is the Subject of the Company’s Investigational New Animal Drug Application for the Indication of General Diarrhea in Dogs

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)

JAGX

ACCESSWIRE

9 months ago

Napo Pharmaceuticals, a Jaguar Health Family Company, Sponsoring Pediatric Gastroenterology Conference in Abu Dhabi and Panel Discussion About Microvillus Inclusion Disease (MVID)

Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care

JAGX

ACCESSWIRE

9 months ago

Napo Pharmaceuticals, a Jaguar Health Family Company, to Exhibit at Oncology Nursing Society (ONS) Congress in Support of Company’s Expanding Focus on Cancer Supportive Care

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

JAGX

ACCESSWIRE

9 months ago

Jaguar Health Appoints Biopharmaceutical Industry Veteran to Execute Company's In-licensing Growth Strategy in the Areas of Cancer and GI Supportive Care

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care

JAGX

ACCESSWIRE

9 months ago

Jaguar Health Licenses FDA-Approved Oral Mucositis Product for U.S. Market, Initiating Commercial Footprint in its Core Focus Area of Cancer Supportive Care

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders

JAGX

ACCESSWIRE

9 months ago

Jaguar Health Reports Approval of All Proposals at April 2024 Special Meeting of Stockholders

Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

JAGX

ACCESSWIRE

9 months ago

Jaguar Health Granted Extension Until August 13, 2024, to Regain Compliance with Nasdaq's Bid Price Requirement

Jaguar Health Full Year 2023 Earnings: US$1.79 loss per share (vs US$36.18 loss in FY 2022)

JAGX

Simply Wall St.

10 months ago

Jaguar Health Full Year 2023 Earnings: US$1.79 loss per share (vs US$36.18 loss in FY 2022)

JAGX

Insider Monkey

10 months ago

Latest Jaguar Health Inc. (JAGX) News on January 19, 2025

Share on Social Networks: